Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. [electronic resource]
Producer: 20080811Description: 94-8 p. digitalISSN:- 1527-3792
- Angiogenesis Inhibitors -- therapeutic use
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents -- therapeutic use
- Benzenesulfonates -- therapeutic use
- Bevacizumab
- Carcinoma, Renal Cell -- drug therapy
- Combined Modality Therapy
- Female
- Follow-Up Studies
- Humans
- Indoles -- therapeutic use
- Kidney Neoplasms -- drug therapy
- Male
- Middle Aged
- Neoplasm Recurrence, Local -- drug therapy
- Nephrectomy -- methods
- Niacinamide -- analogs & derivatives
- Phenylurea Compounds
- Postoperative Complications -- epidemiology
- Preoperative Care
- Pyridines -- therapeutic use
- Pyrroles -- therapeutic use
- Sorafenib
- Sunitinib
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.